BAKER JULIAN

Julian C. Baker is a managing member of Baker Bros. Advisors LP and a long‑time investor in life‑sciences companies. SEC filings and proxy statements list him as a director or reporting person on multiple public biotech issuers and as a significant beneficial owner through Baker Bros. funds.^[1]

Career Background

• Cofounder and managing member of Baker Bros. Advisors LP, a New York‑based investment adviser focused on life‑sciences investing.^[1]
• Longstanding portfolio manager and investor in biotechnology companies; career origins include roles at Tisch Financial Management and the private equity arm of Credit Suisse First Boston, as noted in company proxy disclosures.^[2]
• Frequently appears in Section 16 filings (Forms 3/4/5) and Schedule 13 filings as a reporting person through Baker Bros. funds, reflecting active governance and ownership roles across multiple issuers.^[3]

Current Positions

• Director and significant investor — XOMA Royalty Corporation (ticker: XOMA) and related securities, as reflected in the company’s SEC filings identifying Baker Bros. / affiliated reporting persons.^[4]
• Significant beneficial owner reported for Heron Therapeutics, Inc. (ticker: HRTX) in Schedule 13G/A filings naming Baker Bros. Advisors and Julian C. Baker.^[5]
• Reporting person / beneficial owner filings for Neurogene / Neurogene‑related entities show Baker Bros. and Julian C. Baker listed in Schedule 13 filings.^[6]

SEC Filing Context

• Acts as a reporting person on numerous Form 4 and Schedule 13 filings through Baker Bros. entities; filings commonly reflect director deputization or beneficial ownership disclosed on behalf of affiliated funds.^[3]
• Public filings and proxy statements are the primary sources documenting board service, beneficial ownership and Section 16 reporting for Mr. Baker’s activities.^[2]